Document is current
Any future updates will be listed below
-
Authors
Korbmacher, Max https://orcid.org/0000-0002-8113-2560
Boen, Rune
Andreassen, Ole A. https://orcid.org/0000-0002-4461-3568
Westlye, Lars T. https://orcid.org/0000-0001-8644-956X
Sønderby, Ida E. https://orcid.org/0000-0001-7297-7855
Maximov, Ivan I. https://orcid.org/0000-0001-6319-6774
-
Funding
Funding for this research was provided by:
Norges Forskningsråd (324252)
Norges Forskningsråd (223273)
Ministry of Health and Care Services | Helse Sør-Øst RHF (2022080)
Ministry of Health and Care Services | Helse Sør-Øst RHF (2020060)
EC | Horizon 2020 Framework Programme (802998)
- License Information
-
More Information
Article History
Received: 25 September 2025
Revised: 15 February 2026
Accepted: 6 March 2026
First Online: 19 March 2026
Competing interests
: MK has received a speaker’s honorarium from Merck. OAA has received a speaker’s honorarium from Lundbeck, Janssen, Otsuka and Lilly, and is a consultant to Coretechs.ai and Precision Health. LTW is a minor shareholder of baba.vision. The remaining authors declare no other competing interests.
: The study has been conducted using UKB data under Application 27412. UKB has received ethics approval from the National Health Service National Research Ethics Service (ref 11/NW/0382). All participants gave informed consent.
